Aurobindo arm gets CDSCO SEC recommendation for biosimilar, Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com

The Trastuzumab biosimilar, which is supplied in single dose glass vials containing 150 mg and 420 mg lyophilized powder concentrate for solution for infusion, is a humanised monoclonal antibody for treating metastatic breast cancer and early breast cancer that is human epidermal growth factor receptor 2 positive., The Trastuzumab biosimilar, which is supplied in single dose glass vials containing 150 mg and 420 mg lyophilized powder concentrate for solution for infusion, is a humanised monoclonal antibody for treating metastatic breast cancer and early breast cancer that is human epidermal growth factor receptor 2 positive., , Read More